Fred Gebhart, Contributing Editor
Contributing Editor Fred Gebhart works all over the world as a freelance writer and editor, but his home base is in San Francisco.
VA study leads to call for more rigorous antibiotic stewardship
Antibiotic use is rising at Veterans Affairs medical facilities across the country, according to study findings released recently at the annual meeting of the Society for Healthcare Epidemiology of America in Dallas.
UCSF launches automated pharmacy
Pharmacists at the University of California San Francisco are in the process of bringing one of the world's largest and most advanced robotic pharmacies online.
Routine use of acid-suppressive medication outside ICU questioned
Prophylactic acid suppression is not appropriate for most hospital patients who are not being treated in intensive care, according to researchers at Beth Israel Deaconess Medical Center, in Boston.
CPhA launches employee pharmacist resource program
The California Pharmacists Association has launched what may be the nation's first employee pharmacist ombudsman program sponsored by a state association.
Sam's Club launches preventive healthcare program with pharmacists
Launched in January, The Prevention Plan is an online health-screening and primary prevention program similar to wellness plans already being marketed to employer groups. It costs $99.
Some psychoactive prescription drugs associated with violence
New data suggest that certain prescription drug products are associated with aggression and violence toward others.
FDA restricts dosing of prescription acetaminophen
FDA is limiting the amount of acetaminophen in prescription drug products, primarily combinations of acetaminophen and opioids.
On the right track
Chief executives from key pharmacy organizations met in mid-2010 to reinforce the joint message that the fight to move pharmacy into a central healthcare role has just begun.
USP proposal calls for new prescription label standards
A new prescription drug label format is in the works. Draft standards from the U.S. Pharmacopeial Convention could bring dramatic changes to Rx labels in 2012.
Long-term data support biotech treatment for ITP
Recent data suggest that thrombopoietin receptor agonists are safe and effective for the treatment of chronic immune thrombocytopenic purpura, or ITP, over at least 6 years.

Poll